Saif S Alqassim1, Mauricio Urquiza1, Eitan Borgnia1, Marc Nagib1, L Mario Amzel1, Mario A Bianchet2,1. 1. Structural Enzymology and Thermodynamics Group, Department of Biophysics &Biophysical Chemistry, Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD 21205, USA. 2. Department of Neurology and Department of Biophysics &Biophysical Chemistry, Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD 21205, USA.
Abstract
MICALs (Molecule Interacting with CasL) are conserved multidomain enzymes essential for cytoskeletal reorganization in nerve development, endocytosis, and apoptosis. In these enzymes, a type-2 calponin homology (CH) domain always follows an N-terminal monooxygenase (MO) domain. Although the CH domain is required for MICAL-1 cellular localization and actin-associated function, its contribution to the modulation of MICAL activity towards actin remains unclear. Here, we present the structure of a fragment of MICAL-1 containing the MO and the CH domains-determined by X-ray crystallography and small angle scattering-as well as kinetics experiments designed to probe the contribution of the CH domain to the actin-modification activity. Our results suggest that the CH domain, which is loosely connected to the MO domain by a flexible linker and is far away from the catalytic site, couples F-actin to the enhancement of redox activity of MICALMO-CH by a cooperative mechanism involving a trans interaction between adjacently bound molecules. Binding cooperativity is also observed in other proteins regulating actin assembly/disassembly dynamics, such as ADF/Cofilins.
MICALs (Molecule Interacting with CasL) are conserved multidomain enzymes essential for cytoskeletal reorganization in nerve development, endocytosis, and apoptosis. In these enzymes, a type-2 calponin homology (CH) domain always follows an N-terminal monooxygenase (MO) domain. Although the CH domain is required for MICAL-1 cellular localization and actin-associated function, its contribution to the modulation of MICAL activity towards actin remains unclear. Here, we present the structure of a fragment of MICAL-1 containing the MO and the CH domains-determined by X-ray crystallography and small angle scattering-as well as kinetics experiments designed to probe the contribution of the CH domain to the actin-modification activity. Our results suggest that the CH domain, which is loosely connected to the MO domain by a flexible linker and is far away from the catalytic site, couples F-actin to the enhancement of redox activity of MICALMO-CH by a cooperative mechanism involving a trans interaction between adjacently bound molecules. Binding cooperativity is also observed in other proteins regulating actin assembly/disassembly dynamics, such as ADF/Cofilins.
Growing axons are guided to their appropriate targets by extracellular attractive or
repulsive cues that are essential for proper neuronal growth and development, rewiring,
fasciculation/defasciculation, and nerve regeneration after injury12.
Semaphorins, the most well characterized class of external repulsive guidance molecules,
interact with Plexin and neuropilin receptors on axonal growth cones3.
Upon Plexin interaction with extracellular semaphorins, its cytosolic domain recruits
and activates MICAL (Molecule Interacting with CasL); this activation promotes
reorganization of the cytoskeleton and subsequent growth cone collapse45. Since its initial identification in T-cells6, MICAL has also been
found in a variety of neuronal and non-neuronal cell types in which it controls
cytoskeletal dynamics78.Three MICAL isoforms (MICAL-1, -2, and -3) have been identified in vertebrates45. They have high overall sequence identity (1–2: 56%,
1–3: 56%, and the highest for 2–3: 65% in mouseMICALs). MICALs are
large cytosolic proteins with an N-terminal flavoprotein monooxygenase (MO) domain
containing an FAD cofactor followed by a variable number of protein-interaction
domains3. MICAL-1 combines the catalytic MO domain (residues
1–484) with three other domains thought to be important for modulating
MICAL’s activity and/or interaction with substrates: 1) a CH domain (residues
511–615), 2) a Lin-11 Isl-1 Mec-3 (LIM) domain (residues 666–761)9, and 3) a C-terminal region containing a coiled-coil Ezrin Radixin Moesin
(ERM) domain1011. In addition, MICAL-1 contains a poly-proline PPKPP
sequence (residues 830–834) that binds the SH3 domain of CasL6.In mouseMICAL-1 (mMICAL-1, MW: 117 kDa, 1048 amino acids), the MO
domain (MICALMO) has been shown to reduce molecular oxygen to
H2O2, with a ~70-fold preference for NADPH over NADH
as the source of reducing equivalents12. The structure of
mMICAL-1 MO domain, determined by x-ray diffraction1213,
contains many of the features common to FAD-containing monooxygenases such as
ρ-hydroxybenzoate hydroxylase (pHBH) with one major difference: the cavity that
connects to the active site is larger in MICALMO than in pHBH and could
potentially accommodate a protein substrate; in contrast, pHBH substrates are small
molecules that can be easily accommodated in a small cavity. In the structure determined
in the presence of NADPH, the isoalloxazine ring of the reduced FAD adopts an
“in” conformation, in which it is less accessible to water and to
O213. The CH and other domains of MICAL could play a role
in keeping the active site less accessible to solvent, resembling pHBH and monoamine
oxidases14.CH domains have a highly conserved architecture comprised mainly of
α-helices15. They carry out diverse functions in cytoskeleton
binding and signalling16. The α-actinin and spectrin protein
families, both of which are known to cross-link actin filaments, interact with actin
filaments via two tandem CH domains (classified as type-1 and -2). Some proteins, such
as calponin and IQGAP, contain single CH domains classified as type-3. Smoothelins and
RP/EBs5 as well as MICALs contain a single type-2 CH domain. However,
MICALs are unique in the sense that their CH domain is adjacent to a domain containing
catalytic activity.Hung et al. reported that expression of DrosophilaMICAL constructs
containing either the MO alone or MO plus the CH domain result in proteins with a redox
activity that alters actin polymerization dynamics; specifically, they oxidize Met 44 of
F-actin, leading to destabilization and disruption of actin filaments1718. However, although the MICALMO alone is sufficient to bind and oxidize
F-actin in vitro, in vivo full-length DrosophilaMICAL (dMICAL)
with only the CH domain deleted (MICAL∆CH) shows defects in actin
processing and motor axon guidance1718. For example, in
Drosophila bristles (an in vivo single cell model of MICAL-mediated
F-actin depolymerization), dMICAL co-localizes with F-actin, and the CH domain
participates in this localization, as suggested by the observation that
MICAL∆CH and MICALΔPIR
—lacking the Plexin interacting region—are unable to co-localize with
F-actin17. DrosophilaMICAL∆CH mutants
also show dominant defects in axon defasciculation and guidance1819.
Furthermore, the CH domain is required for MICAL-mediated cytoskeleton organization
in vivo2021. Interestingly, the CH domain of MICAL
(MICALCH) participates in these actin–associated functions even
though the isolated domain does not bind F-actin in vitro2021.
Although it is clear that the MICALCH is functionally important, its relation
to the MO domain and how it modifies the MICALMO activity toward F-actin
remain obscure.The structures of the isolated MICALMO1213 and
MICALCH2021 have been determined, but they do not
provide information about how the CH domain may contribute to connect MICAL activity to
interactions with the cytoskeleton. Understanding the modulation of the
MICALMO catalytic activities by the CH domain requires the determination
of the structure of a MICAL fragment containing the entire MO and CH domains. Here, we
report the structure of a protein containing the MO and CH domains of mMICAL-1
(MICALMO-CH; residues 2 to 615) determined using x-ray diffraction and
small-angle x-ray scattering (SAXS). The structure provides the basis for a model for
the oxidation of Met 44 of actin by MICAL. In addition, using steady-state kinetics, we
demonstrate that the CH domain of mMICAL-1 enhances both recognition of F-actin and
NADPH as well as the NADPH oxidase of MO activity in the presence of F-actin. The high
level of conservation of the MICAL MO and CH domains in species ranging from
Drosophila to Homo sapiens suggest that structural and functional
inferences made here are likely to be applicable to other MICALs, including MICAL-2 and
-3.
Results
Structure Determination
The structures of two crystal forms, native 1 and 2 (Table
1), show electron density for residues 8–486 of the MO
domain and residues 506–554 and 562–614 of the CH domain (Fig. 1). Although no electron density was observed for the
19-residue linker connecting these domains, SDS-PAGE analysis of re-dissolved
crystals shows that no cleavage had occurred during purification or
crystallization that could explain the missing linker (Fig.
2a inset). Although the native 1 crystal was made in the presence of
a large amount (19 mM) of a synthetic actin “D-loop”
peptide (residues 39 to 52 of actin), it did not show additional electron
density for this ligand (hence was named “crystal 1”). The
native 1 structure was refined to an Rwork and Rfree of
0.25 and 0.30 using data to 2.31 Å resolution (Fig. 1). For the native 2 crystal, obtained without the addition of
actin derived peptide, the Rwork and Rfree were 0.23 and
0.28 for data to a resolution of 2.9 Å (Table
1). Size exclusion chromatography showed that, under the conditions
used for crystallization MICALMO-CH is a monomer in solution (Fig. 2). In agreement, both crystal forms analysed contain
one single chain monomer per asymmetric unit.
Table 1
MICALMO-CH data collection and refinement statistics.
Crystal
Native 1
Native 2
Wavelength (Å)
1.5416
Resolution range (Å)
32.14–2.309 (2.392–2.309)
26.81–2.878 (2.981–2.878)
Space group
P 1 21 1
P 1 21 1
Unit cell
71.9 49.9 95.85 90 97.0 90
70.2 50.2 97.0 90 101.2 90
Measured reflections
93863(28540)
52018(14602)
Unique reflections
28284 (2316)
14591 (1005)
Multiplicity
3.3(2.0)
3.6(2.7)
Completeness (%)
94.25 (78.27)
95.03 (65.51)
Mean I/sigma
17.0 (1.2)
6.6 (1.1)
Wilson B-factor
38.33
36.27
R-sym
0.08 (0.49)
0.18 (0.64)
R-work
0.22 (0.27)
0.20 (0.35)
R-free
0.28 (0.37)
0.27 (0.44)
No of non-hydrogen atoms
4776
4608
macromolecules
4518
4510
ligands
61
60
water
197
38
Protein residues
583
581
RMS(bonds)
0.010
0.012
RMS(angles)
1.26
1.35
Ramachandran favored (%)
96
92
Ramachandran outliers (%)
0.69
0.52
Average B-factor
52.70
41.60
macromolecules
53.40
41.90
ligands
38.40
29.00
solvent
41.00
19.40
PDBIds
4TXI
4TTT
#The change in the β angle is the
largest difference between the two crystal forms.
Figure 1
Structure of MICALMO-CH and its different asymmetric unit
choices.
(a) Structure of MICALMO-CH (option 1). Residues of the
actin binding sequence (ABS; 511-EELLHWCQE-519) of the CH domain are shown
in cyan, and residues of the PIP2 binding segment
(521-AGFPGVHVTDFSSSWAD-538) are in green. (b) Another view of the
structure rotated 90o around the vertical axis. (c) A
view showing the four possible choices of asymmetric unit with the symmetry
operations that relates to option 1. MO and CH domains of option 1 are
colour in yellow. CH domains of the other options are coloured in: blue
(option 2), red (option 3), magenta (option 4). The option number is
indicated in the figure. FAD cofactor carbon atoms are shown as green
sticks.
Figure 2
MICALMO-CH is an intact molecule in solution and in the
crystal.
(a) Molecular weight characterized by size exclusion chromatography
MICALMO-CH eluted as a monomer of 61.4 kDa (red line)
in a size exclusion chromatography using a Superose-12 10/300GL (GE
HealthCare) column. Standards are shown in blue, with the molecular weights
(Mw) in kDa indicated. (b) Logarithmic plot of the Mw for the
standards the ratio between elution volume (Ve) and column exclusion volume
(Vo). The pink diamond mark indicates the MICALMO-CH elution
volume observed. (Inset) SDS-PAGE analysis of MICALMO-CH
crystals. Lane 1: crystals dissolved in SDS running buffer after washing
with crystallization mother liquor; lane 2: 10, 15, 20, 25, 30, 40, 50, 60,
70, 80, 90, 100, 110 kDa molecular weight ladder and lane 3:
MICALMO-CH after purification.
Structure of the MO domain
MICALMO contains a Rossman β-α-β fold with a
GXGXXG motif, a sequence common in NADPH-dependent FAD-containing oxidoreductase
enzymes. In both crystal forms the FAD cofactor is oxidized and accessible
through two openings connected to the active site, one large and one small
(Fig. 1a). Alignment of the MO domain of the
MICALMO crystal structure (PDB 2BRA12) to the same
domain of the MICALMO-CH structure shows a 0.5 Å RMSD
for 422 Cα atoms. Only small localized differences are observed
(Supplementary Fig. S1).
Structure of the CH domain
The structure of the CH domain of MICALMO-CH is highly similar to that
of the isolated CH domain of humanMICAL-1 (PDB 1WYL and 2DK9) determined by NMR
methods20 (RMSD of 0.8 Å for
82 Cα atoms; Fig. 3a). As in other CH
domains of the same type found in actin-binding proteins (Fig.
3a–d), the CH domain of MICALMO-CH consists of
three α-helices packed as a parallel bundle, with a fourth
α-helix that is perpendicular to the other three (Fig.
4). As expected from its sequence, the structure of
MICALCH aligns better to the type-2 CH domain of actinin (PDB
2EYI) than to the type-1 (Fig. 3). Key hydrophobic
residues important for helix packing and for binding to F-actin are conserved
(Figs 3d and 4b)152021.
Figure 3
Structure and sequence alignment of MICALCH with characterized CH
domains.
The MICALCH (cyan) align with known type-2 CH domains from
(a) human MICALCH (1WYL, coloured red), (b)
α-actinin (2EYI, coloured pink), (c) spectrin (1BKR, coloured
orange), and (d) dystrophin (1DXX, coloured blue). All four CH type 2
domain align with an RMSD of ~1 Å with most if not
all Cα atoms. (e) Sequence alignment of MICALCH
with the same proteins in (b–d) panels. (f)
Structural alignment of MICALCH with the CH type 1 (rigth) and
type 2 (left) of actinin (PDB 2EYI); MICALCH coloured in cyan,
actinin CH type-1 in green, and actinin CH type-2 in pink.
Figure 4
Overview of the CH domain from MICALMO-CH.
(a) top and side views of the CH domain. Residues comprising the
conserved ABS found in type-2 CH domains are shown in red. Residues that
match the PIP2 binding site in type-2 CH domains are in blue.
(b) CH domain (same view as panel b), highlighting the
residues that makes up the hydrophobic core – represented as magenta
sticks.
The CH domain of MICALMO-CH also shows the other conserved features
found in type-2 CH domains of actin-binding proteins: a conserved actin-binding
segment (ABS; Fig. 4) found in the helix perpendicular to
the other three, and a conserved PIP2 binding site (PBS; Fig. 4)15. In the MICALMO-CH
structure, these segments are exposed to solvent and are free to interact with
other proteins or the membrane (Fig. 1c).
Connectivity between MO and CH domains
There is no observable electron density in either of the two crystal forms for
the 19-residue linker that connects the MO and CH domains. The sequence of this
linker region (residues 488–506) is not well conserved in the different
MICAL-1s (Fig. 5a), in stark contrast to the MO (residues
7–487) and the CH domain (residues 507–611) of MICAL-1, which
show highly conserved sequences from Drosophila to Homo sapiens
(mouse sequences are 91% identical and 93% similar to the MICALMO-CH
region of humanMICAL-1; Supplementary
Fig. S2). Based on sequence, the linker region is predicted to be
unstructured.
Figure 5
Sequence alignments of MICAL-1 CH domain homologues.
MICAL-1 sequences from the indicated organisms were aligned from near the
C-terminus of the MO (aa 458) to the end of the CH domain (aa 615). Residues
in red boxes are conserved among species. The residues participating in the
interaction between the CH and the MO domains of the option 3 are marked
with a triangle, coloured red and blue in the MO domain and CH domain,
respectively. Actin binding sequence (ABS) and PIP binding region (PBS) are
coloured cyan and green respectively only in the mouse sequence. The missing
linker is indicated by a yellow bar bellow the sequence. The secondary
structure elements observed in the structure reported here are displayed on
top of the sequences aligned. Alignment was performed using ClustalW39. Figure prepared with ESPript40.
Lack of density for the peptide connecting between the two domains introduces an
uncertainty as to which of the CH domains among symmetry mates belongs in the
same molecule as a given MO. Examination of the asymmetric unit reveals that,
given the length of the linker (19-residues), the MO could be connected to any
one of four possible CH domains (options 1 to 4, shown in Figs
1c and 6). Equivalent options are present in
both crystal forms.
Figure 6
Asymmetric unit options of crystal 1 showing the modelled linkers between MO
and CH domains.
(a–d) are option 1 to 4 respectively. The five
ab-initio traces of the linker generated by the program
Modeller41 are coloured in red and the ABS of the CH
domain in blue. The FAD carbon atoms are coloured in cyan.
Alignment of the structures of the MO domains of native 1 and native 2 shows that
in the two crystal forms the positions of the four CH domains from alternative
asymmetric units are shifted relative to the MO domain. Aligning the MO domains
of the different options, the root mean square distance between the 103
Cα atoms of the four CH domain options are the largest for option 1 and
4 (8.63 and 8.0 Å, respectively), while those for options 2 and
3 are significantly lower (4.5 Å and 4.6 Å,
respectively). In both crystal forms, options 1, 2, and 4 place the CH domain
far away from the catalytic site (Fig. 6a,b,d), making
minimal contact with the MO domain as indicated by the small buried surface area
(Table 2). The CH domain of option 3 in both forms
buries by far the largest surface area of all four options
(1015 Å2 and
901 Å2; for native 1 and 2 respectively,
Table 2). In this option, the CH docks on the side
of the small entrance to the catalytic site without obstructing it, but it
contacts the catalytic site loop Lc (Fig. 1a). Lc
residues, in particular Trp 405, form the cavity that the isoallozaxine rings of
the (hydroxy)peroxi-C4a-FAD occupies when it swings-in (Figs
1a and 5b)1213. This entrance
may channel the substrate to the C4a-(hydro)peroxy- intermediate site when the
FAD is reduced (Fig. 1a,b). In option 3, the interface on
the CH domain interacting with the MO domain is formed by CH domain helix
α3 and the loop connecting this helix with α4 (Fig. 4). This interface involves Leu 553, Leu 565, Thr 569, Arg 573,
Val 574, Glu 576, His 577, Glu 578 of α3, and Gly 580, Thr 582, Pro 583,
Val 584, Ser 586, and Gln 588 of the loop (Fig. 4c). The
MO side of the interface involves Lys 235, Arg 371, Phe 399, Leu 402, Arg 408,
Gln 441, Leu 442, Ser 444, Gln 445, Ser 447, and Asn 450 (Fig.
5b). Residues on the MO domain participating in the MO-CH interface
are well conserved in vertebrates —to a lesser degree in
Drosophila— (Fig. 5a) as well as among
mouseMICAL isoforms (1–2: 67%,1–3: 62.5%, and notably
2–3: 96% of sequence identity). Residues of the CH domain that
participate in the interface show lower sequence identities between MICAL-2 or
-3 and MICAL-1 (Fig. 5c; 1, 2 and 1, 2,
3: 28.6%), but are highly homologous to each other
(Fig. 5c; 2, 3: 77%). The CH domain residues that participate in this interface,
although they have lower sequence identity with each other than their
counterparts in the MO domain, they do conserve hydropathy and size
characteristics across species and isoforms (Fig.
5a,c).This interaction is mostly polar in nature, and shows significant
charge complementarity. Residues Arg 408 and Glu 576, which form a salt bridge,
are conserved from Drosophila to humans (Fig. 5a)
and among isoforms (Fig. 5c). Also, the NH and the aminenitrogen of Lys 235 form a hydrogen-bonding network with the main chain carbonyl
and the side chain of Glu 578. Another hydrogen bond is observed between the
side chain of Ser 447 and the carbonyl oxygen of Pro 583.
Table 2
Buried surface area between the MO and CH domains in each connectivity
option.
Option
Native 1 (Å2)
Native 2 (Å2)
1
89.8
141.2
2
120.1
261.4
3
1015.0
901.2
4
130.2
138.1
To examine whether it was possible to connect the MO and CH domains of
MICALMO-CH in all four options of native 1, five independent
models of the 19-amino acids linker were generated for each option using the
program MODELLER22. The models show that it is possible to
connect the two domains with a 19-amino-acids linker only for options 1, 2 and 4
(Fig. 6). Linkers for option 3 in mouseMICALMO-CH were predicted to be in highly strained implausible
conformations (Fig. 6c). However, the linkers of
DrosophilaMICAL, and mouseMICAL-2 and -3 are longer than that of MICAL-1 (11,
4 and 6 residues, respectively; Fig. 5c), which could
allow these enzymes to reach an intermolecular association equivalent to
option-3.
Small angle X-ray scattering (SAXS) of MICALMO-CH
SAXS data were obtained to provide independent information about the domain
arrangement and to help resolve the uncertainty in the connectivity. The radius
of gyration (Rg) of MICALMO-CH estimated from the SAXS
data, is 31 Å and the Dmax is 122 Å
(Fig. 7 and Supplementary Fig. S3). The SAXS estimated particle mass,
70.1 kDa, corresponds to the mass predicted from the sequence of the
MICALMO-CH monomer (68.5 kDa,) within 4.4% of error
(Table 3). The experimental Rg is
significantly larger than that estimated for option 3
(Rg = 24.5 Å; Table
3). The other three options predict an Rg significantly
larger than that of option 3, but, still shorter than the experimental value
(Table 3). Option 1 has the smallest discrepancy
between predicted and experimental scattering data
(χ2 = 1.5;
Rg = 28.5 Å) and a close fit to the
low-resolution ab-initio SAXS model (Table 3,
Fig. 7a). The low-resolution ab initio model
(envelope) and rigid body refinement of option 1 using SAXS data indicate a
slightly greater separation between domains in solution than in the crystal
(Fig. 7c,d).
Figure 7
Agreement between models from x-ray scattering and diffraction data.
(a) Adjustment of the experimental SAXS profile of
MICALMO-CH (black scattered points) by the calculated profile
(red solid line) of the crystal structure option 1 (green solid line).
(b) Top and side view of the fitting of the ab-initio
envelope by the crystal structure of MICALMO-CH option 1.
(c) Adjustment of the same experimental profile (scattered
points) by the crystal structure model refined by Sasref (ATSAS) against the
SAXS data. (d) Top and side view of Sasref-refined model fitting of
the ab-initio envelop. The experimental scattering profile was
obtained using the average scattering of three different exposures (0.5, 1,
and 2 sec) of a solution of MICALMO-CH at 7 mg/ml. All the
theoretical profiles were generated using FoXS4243.
Ab-initio envelope fitting was performed using Supcomb (ATSAS)
with “native 1” structure enabling the enantiomorphism
option.
Table 3
MICALMO-CH SAXS Data Collection and Scattering refinement
parameters.
Data collection parameters
Instrument
Beam line SIBYL (LNBL ALS
B12.3.1)
q range [Å−1]
0.0128 - 0.3253
Exposure times [sec]
0.5, 1.0, 2.0, 4.0
Concentration range (mg ml−1)
2.0
4.0
7.0
Structural parameters (from P(r))
I(0) [cm−1]
85.4 (80.1)
216 (199)
413 (398)
Rg (Å) [from P(r)]
31 (31.5)
31.7 (32.4)
32.5(34.1)
Dmax [Å]
114
120
120
Porod’s volume estimate [x
103 Å3]
116(112)
111(103)
107(101)
Dry volume calculated from sequence
[Å3]
81884
Particle-mass estimation/method
Molecular Mass Mr/from I(0); BSA STD [Da] (Δm
%)*
55000 (−19.6%)
Molecular Mass Mr /sasmow,
q < 0.2533 [Da] (Δm
%)*
71500 (4.4%)
Molecular Mass
Mr/Mw = (Vc2
Rg−1/1.231)34
51500
53600
55000
Molecular Mass/Size Exc. Chr. [Da] (Δmass %)*
61455 (−10.2%)
Calculated Mw from sequence + FAD
[Da]
68425
Final NSD of the ab-initio model (σ)
0.47(0.08)
Model Rg (Å)
Fit SAXS χ2
Sasref rigid-body solution
30.4
0.98
Option 1
28.5
1.5
Option 2
27.5
2.2
Option 3
24.3
4.2
Option 4
26.8
2.8
Software employed
Primary data reduction
At the beam-line
Data processing
Scatter 2.01c
Ab-initio analysis
DAMMIN35
Validation and averaging
Damaver (ATSAS)
Rigid-body modeling/refinement
Sasref36
Computation of scattering profiles
FOXS42
Three dimensional graphic representations
Chimera4144/PyMol45
See also Supplementary
Fig. S4. *Difference with respect to the
theoretical mass.
Activity of MICALMO and MICALMO-CH in the presence
of F-actin
F-actin behaves as a non-essential activator of NADPH-oxidation by
MICALMO and MICALMO-CH: the addition of F-actin
increases the rate of reaction but catalysis still takes place in its absence,
albeit at reduced rate (Fig. 8). Consequently, the initial
velocities of the NADPH-oxidation () follow the typical
non-essential activator steady-state kinetics scheme shown in Fig. 8a. These velocities are well represented by Equation (1), a hyperbolic function of the substrate concentration
and activator ([NADPH] and [F-actin], respectively) at given
concentrations of enzyme ([Enzyme]). In Equation (1), the coupling parameter α measures the synergy between
substrate affinity and binding of the activator or vice versa
(α = 1 no coupling, α < 1
positive coupling, etc.), and β measures the acceleration factor of the
turnover-number when the ternary complex (enzyme-substrate-activator) is formed.
The apparent Michaelis-Menten constant () of the
substrate electron donor and apparent turnover-number of NADPH oxidation
() were also obtained by fitting these
velocities at a given [F-actin] with the simple Michaelis-Menten
enzyme/substrate steady-state kinetic equation (2) (Fig. 8b, Table 4). For
MICALMO the values vary only
slightly and not regularly, indicating that actin does not affect the NADPH
binding to the isolated MO domain (Table 4). Therefore,
the observed kinetics for MICALMO can be fit with a constant
(28.8 ± 2.4
μM) across the range of [F-actin] analysed (Fig.
8c, Table 4). The observed independence of
the binding constants (Ks) with the concentration of the other substrate is
modeled with a value of α equal to 1 in Equation (1). In contrast, for MICALMO-CH the values decreases when [F-actin] increases (Fig. 8c and Table 4), suggesting a
value of α different from 1 in Equation (1). Data
were fitted to Eq. (1) restraining α to 1 in the
case of MICALMO and allowing α to vary in the case of
MICALMO-CH. Both sets show good fit to the experimental values
(Fig. 8b). The K constants fitted for
MICALMO and MICALMO-CH are not significantly different
(Fig. 8d; KM of
9.3 ± 1.9 μM vs
10.5 ± 3.4 and KA of
28.8 ± 2.4 μM vs.
37.7 ± 8.4, respectively). In contrast, for
MICALMO-CH the data are fitted with a value α of
0.16 ± 0.04, indicating strong cooperativity between
binding NADPH and actin.
Figure 8
Steady state enzyme kinetics analysis.
(a) Rapid equilibrium diagrams for the system enzyme
(MICALX)/substrate (NADPH)/activator (F-actin). (Left) for
MICALMO and (right) for MICALMO-CH. The
equilibrium constants and rates in each branch are shown with their SE
calculated from the non-linear fit of Equation.
[1] to the initial rate of NADPH oxidation by
MICALMO and MICALMO-CH in presence of F-actin.
(b) Steady state velocities and their fitting with Equation (1) (color traces) and Equation (2) (black traces). The symbol error-bars represent the standard
error of the mean SEMs. (c) Apparent
and of both constructs obtained by the
fitting the initial velocities for each value of [F-actin] with equation
(2). (d) Parameters of the global fitting
of MICALMO and MICALMO-CH using the non-essential
activator (F-actin) Equation (1), the parameter
α was constrained to 1 in the MICALMO dataset. Error bars
represent standard errors (SEs). All fitting and statistical tests were
performed using the program Prism 6 (GraphPad Inc.).
Table 4
Apparent , , and
catalytic power () for both protein
constructs.
MICALMO
[F-actin] μM
0.0
0.45
0.9
2.2
7.5
sec−1
0.68 ± 0.02
0.71 ± 0.03
0.80 ± 0.04
1.18 ± 0.08
1.72 ± 0.11
μM
28.8 ± 2.2
23.3 ± 2.9
24.0 ± 2.8
26.2 ± 4.5
25.5 ± 3.9
sec−1 mM−1
23.6
30.5
33.0
45.5
67.4
MICALMO-CH
[F-actin] μM
0.0
2.0
4.0
8.0
sec−1
1.7 ± 0.5
7.9 ± 0.4
10.0 ± 0.2
10.3 ± 0.15
μM
37.7 ± 8.4
23.9 ± 5.1
17.5 ± 3.0
9.9 ± 2.0
sec−1mM−1
45.1
330.5
571.4
1040.4
In both cases, increases with the F-actin
(activator) concentration, although the magnitude of the change is significantly
greater for MICALMO-CH than that for the isolated MO domain (Fig. 8c,d). The rate of NADPH oxidation by either protein
increases in the presence of actin, but the increase is smaller for
MICALMO
(β = 4.7 ± 0.5 for
MICALMO;
β = 7.43 ± 0.31 for
MICALMO-CH;
Fig. 8d). The dependence of the Ks for NADPH and
actin on each other’s concentration in MICALMO-CH is the
major difference between the two proteins (α = 0.16 for
MICALMO-CH vs. 1.0 for MICALMO).
Model of MICALMO-CH/F-actin interaction
As the D-loop of actin is part of a large oligomeric filament (F-actin) it raises
the question of whether it is accessible to the active site of MICAL. For a
direct oxidation to be possible, the sulfur atom of Met 44 (well
below the surface in F-actin) should be positioned within
~3 Å of the C4a (hydroxyl)peroxy-FAD- intermediate so
that oxidation can occur. Thus, a conformation should be found in which the
actin D-loop of a filament comes close to the C4a of the FAD cofactor in a way
that allows the oxidation to take place. This conformation should be accessible
from observed structures without breaking any covalent bonds or affecting the
structural integrity of either actin or MICAL.As no crystal structure of MICAL in complex with F-actin is available, we built a
possible model of the complex (Fig. 9a,b), using the
MICALMO-CH crystal structure and a dimer of actin from the most
recently reported F-actin model (PDB 2ZWH23). The CH domain of
MICAL was essential in choosing the initial position and the orientation of
MICALMO-CH on the F-actin; we hypothesize that the CH domain is
necessary for optimizing the binding of the MO to oxidize Met 44. The initial
position was chosen based on aligning the CH domain of MICALMO-CH and
the CH of actinin bound to actin (PDB 3LUE24), followed by manual
adjustment to bring both the MO and CH domains in close proximity to the actin
dimer (Fig. 9a,b). Although Met 44 is far from the
surface, the wide opening of the MICAL’s active site can be oriented
towards the D-loop. This model served as a starting point for a series of
molecular dynamics simulations in which, in each successive run, actin’s
Met 44 was harmonically constrained with a soft force constant (0.5 kcal
mol−1 Å−2) to be
closer to FAD-C4a, until its sulphur atom was within
~3 Å of the FAD-C4a.
Figure 9
Model of MICALMO-CH/F-actin interactions.
(a) Starting model used in the MD runs, MICALMO-CH option 1
(yellow cartoon) docked in the electron microscopy model of the F-actin
filament (PDB-ID: 3LUE). The CH domain ABS is coloured in cyan. The actin
filament is represented as solvent accessible surface with each actin
monomer coloured differently. The position of the CH type 2 of the electron
microscopy structure of actinin is indicated by a red outline. (b)
Same drawing from panel a with the solvent accessible surface of the
CH type 2 domain of actinin coloured dark green. (c) Final structure
of the actin monomer with the FAD of MICALMO-CH in the
“out” position (oxidized) and (d) with the FAD in the
“in” position (reduced). See also Supplementary Figure S7 in supporting
information.
The simulations reveal that it is possible to attain a D-loop conformation in
which Met 44 is in proximity to FAD-C4a (hereafter referred to as
“D-loop out” conformation); shown in Fig.
9c,d. A conformation with Met 44 close to the FAD-C4a is possible
regardless of whether the FAD of the MO domain is in the oxidized
“out” or the reduced “in” conformation. The
potential energy, averaged over the production phase of the simulation, of the
“D-loop out” conformation is within 3% of that of the original
conformation23 (Table 5). The major
structural change in the actin monomer is in the D-loop itself and the few
residues surrounding it; the rest of the actin monomer remains close to the
original structure (Fig. 9c,d). The fact that this
“D-loop out” conformation can be reached in a molecular dynamics
simulation, using gentle steering and without the need to break bonds or
significantly alter the integrity of either structure, indicates that this
conformation can be populated with a high enough frequency to be kinetically
competent.
Table 5
Average energies from molecular dynamics simulations of MICALMO-CH
and F-actin.
Initial
D-loop out (FAD oxidized)
D-loop out (FAD reduced)
Bond
1004.31
1008.50
1006.45
Angle
2560.50
2563.94
2556.54
Dihedral
1930.89
1917.22
1905.48
Improper
177.15
180.15
179.40
van der Waals
−1804.69
−1869.97
−1856.41
Electrostatic
−593.64
−628.71
−616.30
Harmonic
3.97
4.85
3.47
All energies reported are in kilocalories per mole.
Discussion
Our studies provide novel insights into the role of the MICALCH domain in
modulating the catalytic activity of MICAL towards F-actin. This work also reports
the first example to date of a CH domain modulating the activity of an adjacent
catalytic domain.In the two crystal structures of the MICALMO-CH presented here, the
structures of the MO domain and the CH domain are similar to those of the isolated
domains. As no electron density is found for the linker connecting the two domains,
which of the CH domains in the asymmetric unit is connected to the MO domain cannot
be decided from the structure.To resolve the ambiguity, SAXS data of MICALMO-CH in solution were
collected. The ab-initio low-resolution envelopes and rigid-body refinement
using the SAXS scattering data (Fig. 7) indicate that in
solution MICALMO-CH is an elongated molecule that resembles
crystallographic option 1 (Fig. 6a) but with a slightly larger
separation between domains (Fig. 7d). This larger separation
is compatible with a flexible linker between the two domains. The fact that none of
the possible MO-CH arrangements are identical between the two crystal forms also
supports the argument that there is conformational flexibility between the two
domains.What is immediately evident upon inspection of the structures is that the CH domain
does not significantly alter the conformation of the MO domain nor does it obstruct
the active site, regardless of the choice of asymmetric unit (Fig.
1c).A characteristic feature of this monooxygenase family is that binding of the
oxygen-acceptor substrates (i.e. F-actin) accelerates NADPH oxidation. In these
enzymes the loss of reducing equivalents by production of peroxide is actively
suppressed; however, leakage velocities between 1 and
2 s−1 are frequently observed. Both MO and MO-CH
show low turnover rates (0.7 and 1.7 s−1,
respectively) in the absence of F-actin. The suppression is relieved by the oxygen
acceptor substrate and accelerations between
102–105 fold have been observed in
aromatic monooxygenases25.Acceleration of NADPH oxidase activity in the presence of similar amounts of F-actin
for different MICAL domain combinations and species have been reported: acceleration
of 5-fold for human MICALMO in presence of 2.4 μM
of F-actin26, 35-fold i in DrosophilaMICALMO-CH in
presence of 2.3 μM Drosophila F-actin17, and
recently a 10-fold across all humanMICALMO-CH types (MICAL-1, 2, and 3)
in presence of 2.8 μM F-actin27. In contrast, we
observed moderate 1.7-fold increase for our mouse MICALMO and 4.7-fold
for the MICALMO-CH construct in the presence of 2 μM of
F-actin (Table 4). Different degrees of inhibition by the
buffer used in the experiments —we choose to maximize F-actin polymeric
state— or differences between species may be the cause of the discrepancies
observed. There is agreement nevertheless, between our data, the human data, and the
DrosophilaMICALMO-CH in that all three show acceleration in
the rate of NADPH oxidation in the presence of F-actin.Interestingly, the reducing equivalents consumed in the time interval used for
velocity determination (5–10 s) exceed the amount of activator
present in some conditions (for example for 0.4 μM of F-actin;
Table 4). The NADPH oxidation profiles (Supplementary Fig. S4) show an early deviation
(curvature) from the initial slope that may be associated with a second phase with
depleted activator. The NADPH oxidation rate by DrosophilaMICAL is
0.8 μM of NADPH per second (estimated from Fig.
1F of ref. 17 using the described sampling
of 10 s). There dMICAL would have processed sufficient reducing equivalents
at the first data point to oxygenate all the F-actin (2 μM) present
in the reaction several times, suggesting that either (a) not all the NADPH consumed
is used to modify the bound F-actin, (b) there is more than a single site of
modification per F-actin molecule, or (c) the modified F-actin continues to activate
the redox reaction independent of or in addition to being a substrate.Overall, MICALMO and MICALMO-CH catalyse the oxidation of NADPH
faster (β > 0) in presence of F-actin but with different
kinetic characteristics (Fig. 8). There are significant
differences between catalytic activities
(kcatMO < kcatMO-CH)
and acceleration factors
(βMO < βMO-CH),
consistent with further enhancement of the redox activity with F-actin when the CH
domain is present. In the range of F-actin concentrations tested, the apparent redox
catalytic power increases more than 20-fold in the case of MICALMO-CH; in
contrast to the modest 3-fold increase observed in the case of MICALMO
(Table 4). F-actin accelerates NADPH oxidation more for
MICALMO-CH than for MICALMO
(β = 7.4 ± 1.3 vs.
4.9 ± 0.4; Fig. 8c). The CH domain
does not change the affinity for each substrate alone
—KMMO is not significantly different
from KMMO-CH and
KAMO ≈
KMO-CH; Fig. 8d.
The difference between the two proteins, MICALMO and
MICALMO-CH, is found in the kinetics of oxidation of actin. In the
case of the single MO domain, F-actin functions as a simple non-essential activator
that provides an alternative path for the oxygenation reaction to occur, resulting
in an increase of the NADPH oxidation rate without changes in NADPH affinity
(α = 1). In contrast, in MICALMO-CH, in addition
to this effect, F-actin modifies the MO active-site in a way that increases the
affinity for NADPH (α = 0.16) and its oxidation rate. These
observations suggest that the CH domain functions by coupling second
substrate-binding to enzymatic rate enhancement.Of the possible MO-CH arrangements in the crystal asymmetric unit, option 3 shows the
most compact structure with the closest and the tightest interactions between the MO
and CH domains (Fig. 6c). The characteristics of this
interaction—buried area (≈1000 Å2),
charge complementarity, and the degree of conservation of the interface residues
among species and isoforms—suggest that this contact may have a
physiological role as an intermolecular interaction between the MO and the CH
domains. MICAL-2 and MICAL-3 have longer linkers and high residue conservation in
the putative MO-CH interface (Fig. 5c), providing additional
indirect evidence that these interfaces may be a hot spot for a protein-protein
association with biological relevance in these isoforms.The failure of option 3 to explain the SAXS results (Table 3,
Fig. 7) argues against this being the actual arrangement
between the two domains in solution. However, the CH domain placement far away from
the active site in all the other options makes it physically improbable that the
covalently connected CH domain may have a direct effect on the MO activity.This apparent contradiction may be explained by a trans cooperative mechanism
in which the CH domain from one MICALMO-CH molecule interacts with the MO
domain of another MICAL via the option 3 interaction. This interaction is
particularly suited for trans binding because the cis interaction is
unfavorable given the length of the linker peptide (see above). Actin
depolymerization factors ADF/Cofilins are a well-characterized family of
filament-severing proteins that also show a common cooperative mechanism of
action28.In summary, the structures in crystal and solution of MICALMO-CH presented
in this study provide structural insight into the function of MICAL’s CH
domain. The CH domain couples binding of F-actin to catalytic site modification
enhancing the monooxygenase activity. In this CH-mediated mechanism, cooperative
binding of MICAL molecules, perhaps using the contact observed in option 3, appears
to be involved. This cooperative binding further stabilizes the formation of the
MICAL/F-actin complex, while at the same time allowing the non-covalent
concatenation of MICAL molecules on the surface of the filaments that will
significantly increase the efficiency of actin modification by MICAL. The contact
between the CH domain and the catalytic site loop Lc (Fig. 5b)
provides a mechanism for modulating both substrate affinity and catalytic
activity.Our F-actin/MICALMO-CH model suggests that direct oxidation of actin Met
44 by MICAL is possible; however, it does not rule out that oxidation of Met 44
occurs by a high local H2O2 concentration in the cavity formed
upon binding MICALMO-CH to actin. Restricted access of the
H2O2 to the sulfur atom of Met 44 may result in an
apparent stereospecificity2930. The model for oxidation of F-actin
by MICAL presented here involving a large change in the conformation of the D-loop
of actin will be important for guiding future experiments aimed at elucidating
mechanistic details of the redox reaction catalyzed by MICAL.
Methods
Cloning
A plasmid containing DNA coding for residues 2–615 of MICAL-1 from Mus
musculus, codon-optimized for expression in Escherichia coli was
obtained from Genescript Inc. In addition of a Gly from the expression
vector digestion site, the Q78K substitution was introduced to remove an
endogenous protease site. This construct, cloned onto a pET28a expression vector
containing an N-terminal His-tag with an engineered N-terminal Tobacco
Etch virus (TEV) protease site, was used to transform Escherichia
coli BL21.
Protein expression and purification
After induction of the transformed E. coli cells by addition of
0.2 mM isopropyl-β-D-thiogalactoside (IPTG), cells were grown
for 15 hours at 17 °C in LB media before harvesting by
centrifugation. Cells were resuspended in lysis buffer (50 mM Tris-HCl
pH 7, 140 mM NaCl, 10 mM imidazole, 0.1% Tween-20, 5 mM
MgCl2, 2 mM β-mercaptoethanol, 5 mM
benzamidine, and 10% v/v glycerol) and broken with a microfluidizer. After
centrifugation and filtering, the protein was purified by Ni-Sepharose affinity
chromatography with a gradient of 10–500 mM imidazole in
50 mM Tris-HCl pH 7.3, 140 mM NaCl. The eluted protein was
dialyzed against 50 mM Tris-HCl pH 7.0, and 200 mM Glycine, and
digested overnight with TEV protease to remove the His-tag. The cleaved product
was purified using a Source 15S cation exchange column (GE Healthcare), eluting
with 50 mM Tris-HCl pH 7.0, and a 0–1 M NaCl gradient.
The final yield was ~3 mg per liter of culture.
MICALMO-CH was concentrated to ~25 mg/ml using a
3 kDa MWCO ultrafiltration device (GE Healthcare), before storage at
−80 °C.The mouse MICALMO (1–484) used in the enzyme kinetic
experiments described below was prepared as previously described12.
Crystallization (Native 1)
1 μl of MICALMO-CH protein solution (25 mg/ml
in 50 mM Tris-HCl pH 7.0, 200 mM NaCl, 2 mM DTT, 2% v/v
glycerol) was mixed with 1 μl of a 19.0 mM peptide
solution of actin’s D-loop (39-RHQGVMVGMGQKDS-52) and incubated at room
temperature for 30 min. Two μl of this solution, combined with
1 μL of reservoir solution (100 mM HEPES pH 7.0, 20% PEG
2000 MME) and equilibrated against 500 μl of reservoir
solution, produces small crystals of poor diffracting quality. Single crystals
suitable for data collection were obtained by a two additional steps: 1) drops
were micro-seeded by hair-streaking of the crystallization drops after a day of
equilibration after touching the previous crystals with the hair; and 2) a new
crystallization round mixing protein aliquots with a seed dilution generated by
smashing a few of the previously obtained crystals in reservoir solution. After
this final step, suitable single crystals grew in 24 h at
20 °C.
Crystallization (Native 2)
For crystallization, the protein solution (25 mg/ml) was prepared in a
buffer containing 100 mM sodium citrate pH 5.0, 200 mM NaCl.
Differential scanning fluorimetry showed high stability of the protein in this
buffer condition (data not shown). 1 μl of this protein solution
was combined with 1 μl of microseeds diluted in reservoir
solution [100 mM HEPES pH 7.0, 20% PEG 2000 MME] and
equilibrated against 500 μl of reservoir solution. Crystals grew
in 24 hours at 20 °C.
Crystal Data Collection, Structure Determination, and
Refinement
Cell parameter variations among crystals obtained in the same conditions during
the search for diffraction quality crystals were frequently observed (data not
shown). Two crystal forms showing differences in the
cell-dimension and β angle were selected for analysis. Diffraction data
from both crystal forms (native 1 and native 2) frozen in the their mother
liquors, with 20% v/v glycerol added as cryoprotectant, were collected using a
Saturn 944 + CCD as a detector. The source was an
FR-E + Super-Bright copper
rotating anode x-ray generator equipped with VariMAX™ mirrors for
monocromatization and collimation (Rigaku Americas Corporation, The Woodlands,
TX). Data were processed with HKL2000 (HKL Research Inc.). The structure of
native 1 was determined by molecular replacement with the program MOLREP as
implemented in the CCP4 Suite31, using the previously determined
structure of MICALMO (residues 1–484) as a search model (PDB
2BRA12). The model of the CH domain was built manually with
the program COOT32 on the unassigned electron density of a
sigmaA-weighted difference Fourier map (mFO-DFC)
calculated with phases from the MO domain alone. The final structure was refined
using the program REFMAC in CCP4 Suite). The structure of the second crystal was
determined by molecular replacement using the two domains of the first crystal
as separate search models. The models were refined by rigid body refinement,
followed by restrained refinement and TLS/Restrained refinement (Fig. 1). All data collection and refinement statistics are presented
in Table 1.
Size exclusion chromatography
The oligomeric size of MICALMO-CH in solution was determined using
size exclusion chromatography (SEC) with a Superose™ 12 10/300 GL column
(GE LifeSciences) in a buffer containing 50 mM Tris-HCl pH 7.0 and
500 mM NaCl. Five molecular standards of known size (Thyroglobulin,
Globulin, ovalbumin, myoglobin, and vitamin B12) were used for calibration in an
independent run. The elution position of the MICALMO-CH peak compared
to those of the five standards (Fig. 2a) was used to
estimate the molecular weight (Mw) using the relation between the log(Mw) and
the ratio between the sample elution volume (Ve) and the column void volume (Vo)
(Fig. 2B).SAXS data were collected at the SIBYLS beam line (B12.3.1) of the ALS for q
values in the range
0.0128–0.3253 Å−1 using three
protein concentrations (2, 4 and 7 mg/ml) in a buffer containing
50 mM TrisHCl pH 7.0, 200 mM NaCl, 2 mM DTT, and 2% v/v
glycerol (Table 3). The particle molecular mass was
estimated by three independent methods (Table 3 and Suppl. Fig. S4): a) using the
relation between the intensities of the scattering at zero angle [I(0)] of the
MICALMO-CH sample and that of a standard -dimeric bovine serum
albumin (BSA; Mw: 132 kDa, SIGMA Inc.)- at the same three concentrations
used for the protein sample; b) using the saxsmow web server estimator (http://www.ifsc.usp.br/~saxs/saxsmow.html)33; and
c) using the relation between the molecular weight and the ratio of the square
of the correlation volume (Vc) to Rg as implemented in Scatter
2.034. An ab-initio low-resolution model of
MICALMO-CH was obtained by a two-step procedure. In the first
step, twenty envelopes were generated by DAMMIN (ATSAS) and averaged with
DAMAVER (ATSAS) to provide a low-resolution dummy atom model (DAM) with an
overall normalized spatial discrepancy (NSD) of 0.735. In a
second step, the averaged DAM generated by DAMAVER was used as a starting model
for a final run of DAMMIN. The final low-resolution model (Fig.
7) has an averaged NSD of 0.47 with a standard deviation of 0.08. In
addition, an all atom-model, obtained by rigid-body refinement of the two
separated MICALMO-CH domains against the experimental scattering
using the program SASREF36, reached a χ2
of ≈0.69 (Fig. 7).
Rate of NADPH oxidation as a function of F-actin concentration
MICAL’s constructs redox activity in presence of F-actin was measured as
NADPH oxidation monitoring the decrease in absorbance at 340 nm over
time (Fig. 8, Supplementary Fig. S5). The reaction was initiated with the addition
of the enzyme to a 100 μL quartz-cuvette and mixing for
5 sec by slowly pipetting to avoid bubbles. To maintain steady-state
conditions in NADPH and F-actin, the rate of reaction was measured as close as
possible to the beginning of the reaction, commonly after 5 sec and
before 10 sec. The initial slope of the curve was taken as the initial
reaction-rate of NADPH oxidation () (See Supplementary Fig. S5 for a example of the
observed curves). Kinetic data for MICALMO and MICALMO-CH
were obtained at different NADPH concentrations (six data points ranging from 3
to 100 μM for the MO and five data points from 10 to
150 μM for the MO-CH) for each F-actin concentration used (five
conditions 0.0, 0.4, 0.9, 2.2, and 7.5 μM for the MO and four
conditions 0.0, 2.0, 4.0, and 8.0 μM for the MO-CH). Each data
point was repeated three to four times and the mean and its
standard deviation recorded. Data from each construct were fitted using the
general steady-state kinetic relation in the presence of a non-essential
activator known as a Henri-Michaelis-Menten relation given by the equation (1).in which K and K are the
equilibrium constants in the quasi-equilibrium conditions depicted in Fig. 8a for NADPH (substrate) and F-actin (activator),
assuming non-limiting amounts of these, α is the ratio between substrate
affinities of the free enzyme and activator-bound enzyme, β is the
acceleration factor produced by the activator (F-Actin), and the turnover number, where is the initial reaction rate at infinite concentration of substrate.
Bracketed variables are the concentration of the reaction components. Evaluating
equation (1) at a given concentration of F-actin simplifies
to the relation for a simple enzyme-substrate reactionIn which the apparent NADPH dissociation constant () and catalytic rate ()—now
functions of the activator concentration—are related to the absolute
constant parameters in equation (1) by:The turnover numbers (kcat) of MICALMO and
MICALMO-CH at different concentrations of F-actin are shown in
Fig. 8. Kinetic parameters were determined by
non-linear least-squares fit of , to the equation
(1) using the program Prism6 (GraphPad Inc.), which was
also used for the statistical analysis. Human non-muscle G-actin (from human
platelets; #APHL99, Cytoskeleton Inc.) was polymerized following manufacturer
protocols. The polymerization buffer: 5 mM TrisHCl pH 8.0, 50 mM
KCl, 2 mM MgCl2, 0.2 mM CaCl2,
0.5 mM DTT, 1 mM ATP was used in the steady-state kinetic
experiments.The concentration of the MICAL constructs used (600 nM) was determined by
absorbance at 280 nm of a sample denatured in 6 M GdnHCl using
the Gill and von Hippel method37.The statistical analysis were performed using an F-square sum F-test for each
dataset fit with Equation (2) as is implemented in the
program Prizm® v 6.0.
Modelling of the MICALMO-CH complex with actin
A model of the complex of MICALMO-CH and F-actin was made using the
crystal structure of MICALMO-CH reported in this study and a dimer of
actin from the most recent F-actin model (PDB 2ZWH38). In the
case of the reduced enzyme, the MO in the MICALMO-CH structure was
replaced by the one in the crystal structure of the MO with the reduced FAD (PDB
2C4C13). To obtain a starting model, the CH domain of
MICALMO-CH was aligned to the CH domain of an electron microscopy
model of actinin bound to F-actin (PDB 3LUE24), followed by
manual adjustment of MICALMO-CH to orient the large opening of the
active site in the MO towards the D-loop (DnaseI-binding loop) of actin which
contains Met 44, while maintaining the contact between the CH domain and actin.
In these conditions, the closest distance between Met 44 and the C4a of the FAD
is ~32 Å. For direct oxidation to be possible, the
D-loop must adopt a conformation in which the sulfur atom of Met 44 is within
~3 Å of the distal oxygen of the C4a-hydroperoxyflavin
FAD intermediate (FAD-C4a-O-OH) of MICAL’s active site. To assess
whether such a conformation is possible, we used a series of steered molecular
dynamics (MD) calculations. CHARMM version 28b2 with the CHARMM 28b2 force field
was used in the computations with implicit solvent and a distance dependent
dielectric constant. The models were optimized by minimizing the energy for 1000
cycles of steepest descent, followed by 1000 cycles of conjugate gradient, and
finally 1000 cycles of adopted-basis Newton-Raphson minimization. For all MD
calculations, the FAD cofactor was harmonically constrained to either the
oxidized “out” conformation or the reduced “in”
conformation with a soft force constant (1 kcal
mol−1 Å−2). Leapfrog
Verlet molecular dynamics simulations were performed at a constant temperature
of 300 K and ran for 30,000 fs, harmonically constraining Met 44
to a chosen position with a force constant of 0.5 kcal
mol−1 Å−2). In
each successive simulation, Met 44 was constrained to a position closer to the
FAD-C4a atom, until the D-loop achieved a conformation where Met 44 was within
the 3 Å range required for oxidation to be possible. The average
value of the energy and its fluctuations during the last 10,000 fs were
calculated with an in-house written program.
Additional Information
How to cite this article: Alqassim, S. S. et al. Modulation of MICAL
Monooxygenase Activity by its Calponin Homology Domain: Structural and Mechanistic
Insights. Sci. Rep. 6, 22176; doi: 10.1038/srep22176 (2016).
Authors: Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin Journal: J Comput Chem Date: 2004-10 Impact factor: 3.376
Authors: Alessandro Esposito; Valeria Ventura; Maxim V Petoukhov; Amrita Rai; Dmitri I Svergun; Maria A Vanoni Journal: Protein Sci Date: 2018-10-31 Impact factor: 6.725
Authors: Klitos Konstantinidis; Vassilios J Bezzerides; Lo Lai; Holly M Isbell; An-Chi Wei; Yuejin Wu; Meera C Viswanathan; Ian D Blum; Jonathan M Granger; Danielle Heims-Waldron; Donghui Zhang; Elizabeth D Luczak; Kevin R Murphy; Fujian Lu; Daniel H Gratz; Bruno Manta; Qiang Wang; Qinchuan Wang; Alex L Kolodkin; Vadim N Gladyshev; Thomas J Hund; William T Pu; Mark N Wu; Anthony Cammarato; Mario A Bianchet; Madeline A Shea; Rodney L Levine; Mark E Anderson Journal: J Clin Invest Date: 2020-09-01 Impact factor: 14.808
Authors: Elena E Grintsevich; Hunkar Gizem Yesilyurt; Shannon K Rich; Ruei-Jiun Hung; Jonathan R Terman; Emil Reisler Journal: Nat Cell Biol Date: 2016-07-25 Impact factor: 28.824